Predictors of the efficacy of radioiodine therapy of Graves’ disease in children and adolescents

RATIONALE: Insufficient world–wide clinical experience in radioiodine therapy (RIT) for Graves’ disease (GD) in children and adolescents, and limited knowledge of the predictors of RIT efficacy.

AIMS: Analysis and identification of the most significant predictors of the efficacy of RIT in children and adolescents with Graves’ disease.

MATERIALS AND METHODS: A total of 55 patients (48 females and 7 males) aged from 8 to 18 years receiving primary RIT for GD were enrolled. RIT planning was based on the dosimetric method. Analyzed parameters included gender, age, ultrasound thyroid volume before and 6 months after treatment, the presence of endocrine ophthalmopathy, duration of antithyroid drug (ATD) therapy, relapse of thyrotoxicosis after ATD dose reduction, blood fT3, fT4 and TSH levels initially and at 1, 3, 6 months after treatment, TSH receptor Ab initially and at 3 and 6 months after treatment, thyroid ^99mTc–pertechnetate uptake at 10–20 minutes (%), maximum thyroid ¹³¹I uptake (%), specific ¹³¹I uptake (MBq/g) and therapeutic ¹³¹I activity (MBq). Fisher exact test, non–parametric Mann–Whitney test, Wilcoxon signed–rank test, logistic regression modelling, ROC–analysis, proportional hazard model (the Cox regression), the Kaplan–Meier method and log–rank test were used for statistical analysis as appropriate.

RESULTS: Six months after RIT, hypothyroidism was achieved in 45 (81.8%), euthyroid state – in 2 (3.6%), and in 8 (14.6%) patients thyrotoxicosis persisted. On univariate statistical analysis, the smaller thyroid volume, higher fT4 and lower TSH receptor Ab levels, lower ^99mTc–pertechnetate uptake and higher specific ¹³¹I uptake were associated with hypothyroidism. On multivariate logistic regression analysis, the older patient’s age (p=0.011), smaller thyroid volume (p=0.003) and higher fT4 (p=0.024) were independent predictors of RIT efficacy. Thyroid volume was also the only variable associated with achievement of hypothyroidism in time after RIT (p=0.011).

CONCLUSION: The efficacy of dosimetry–based RIT in children and adolescents with GD 6 months after treatment was 81.2%. Older patients’ age, smaller thyroid volume and higher fT4 level were independent predictors of therapy success. Smaller thyroid volume was also a predictor of the favorable time–related outcome. Statistical models obtained in this work may be used to prospectively estimate the chance of efficient RIT for GD in pediatric patients.

1. Kraiem Z, Newfield RS. Graves’ disease in childhood. J Pediatr Endocrinol Metab. 2001;14(3):229–243. doi: 10.1515/jpem.2001.14.3.229.

2. Muratova ST, Ismailov SI. Mental characteristics of teenagers with Graves’ disease in Uzbekistan. European science review (Vienna). 2015;7-8:77–80.

3. Chernyshova VS, Stol’nikova TG, Evtukhova OV, Kulakova EN. Osobennosti klinicheskoy kartiny diffuznogo toksicheskogo zoba u detey Voronezhskoy oblasti. Meditsina: teoriya i praktika. 2019;4(S):601. (In Russ.).

4. Glaser NS, Styne DM. Organization of Pediatric Endocrinologists of Northern California Collaborative Graves’ Disease Study G. Predicting the likelihood of remission in children with Graves’ disease: a prospective, multicenter study. Pediatrics. 2008;121(3):481–488. doi: 10.1542/peds.2007-1535.

5. Takaya K, Kimura N, Hiyoshi T. Antithyroid arthritis syndrome: a case report and review of the literature. Intern Med. 2016:55(24):3627–3633. doi: 10.2169/internalmedicine.55.7379.

6. Nikitopoulou E, Gazi S. Antithyroid drug induced syndrome that lies in between ANCA vasculitis and lupus-like syndrome in a 40-year-old female with Graves’ disease under methimazole therapy: A Case report. Mediterr J Rheumatol. 2018:19;29(1):52–54. doi: 10.31138/mjr.29.1.52.

7. Ismailov SI, Khayitboeva KK. Problems of diagnostics and treatment of diffuse − toxic goiter (Graves’ disease). Vestnik of Saint Petersburg University. Medicine. 2019;14(2):98–104. doi: 10.21638/spbu11.2019.202.

8. Rumiantsev PO, Sheremeta MS, Kiyaev AV, et al. Efficacy and safety of radioiodine treatment of Graves’ disease in children and adolescents. Clinical and experimental thyroidology. 2017;13(1):6–11. (In Russ.). doi: 10.14341/ket201716–11.

9. Bezlepkina OB. Federal clinical guidelines for the diagnosis and treatment of Graves’ disease in children. Problems of Endocrinology. 2014;60(3):59–68 (In Russ.). doi: 10.14341/probl201460359-68.

10. Kahaly GJ, Bartalena L, Hegedüs L, et al. 2018 European thyroid association guideline for the management of graves’ hyperthyroidism. Eur Thyroid J. 2018;7(4):167–186. doi: 10.1159/000490384.

11. Rumiantsev PO, Korenev SV. The history of radioiodine therapy beginnings. Clinical and experimental thyroidology. 2015;11(4):51–55. (In Russ.). doi: 10.14341/ket2015451-55.

12. Rumiantsev PO, Kiyaev AV, Sheremeta MS, Chikulaeva OA. Radioiodine therapy of thyrotoxicosis in children and adolescents. Indications, efficacy and safety. Literature review. Endocrine surgery. 2016;10(4):6–12. (In Russ.). doi: 10.14341/serg201646-12.

13. Gambhir S, Barai S. Radioiodine for treatment of graves’ disease in pediatric population: an ideal treatment. World J Endocr Surg. 2010;2(2):77–80. doi: 10.5005/jp-journals-10002-1026.

14. Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016;26(10):1343–1421. doi: 10.1089/thy.2016.0229.

15. Stokkel MP, Handkiewicz Junak D, Lassmann M, et al. EANM procedure guidelines for therapy of benign thyroid disease. Eur J Nucl Med Mol Imaging. 2010;37(11):2218–2228. doi: 10.1007/s00259-010-1536-8.

16. Pandey M, Jain A. ROC Curve: Making way for correct diagnosis. SP11-PharmaSUG 2016 [Internet]. Available from: https://www.pharmasug.org/proceedings/2016/SP/PharmaSUG-2016-SP11.pdf.

17. Rivkees SA, Cornelius EA. Influence of iodine-131 dose on the outcome of hyperthyroidism in children. Pediatrics. 2003;111(4 Pt 1):745–749. doi: 10.1542/peds.111.4.745.

18. Kaplowitz PB, Jiang J, Vaidyanathan P. Radioactive iodine therapy for pediatric Graves’ disease: a single-center experience over a 10-year period. J Pediatr Endocrinol Metab. 2019;33(3):383–389. doi: 10.1515/jpem-2019-0316.

19. Namwongprom S, Unachak K, Dejkhamron PМ, et al. Radioactive iodine for thyrotoxicosis in childhood and adolescence: Treatment and outcomes. JCRPE J Clin Res Pediatr Endocrinol. 2013;5(2):95–97. doi: 10.4274/Jcrpe.951.

20. McCormack S, Mitchell DM, Woo M, et al. Radioactive iodine for hyperthyroidism in children and adolescents: referral rate and response to treatment. Clin Endocrinol (Oxf ). 2009;71(6):884–891. doi: 10.1111/j.1365-2265.2009.03565.x.